Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice by Morita, Katsuya et al.
 1
DEVELOPMENT OF TACTILE ALLODYNIA AND THERMAL 
HYPERALGESIA BY INTRATHECALLY ADMINISTERED 
PLATELET-ACTIVATING FACTOR IN MICE 
 
1Katsuya Morita, 1Norimitsu Morioka, 1Joynal Abdin, 2Shigeo Kitayama, 3Yoshihiro 
Nakata, 1Toshihiro Dohi* 
 
1Department of Dental Pharmacology, Division of Integrated Medical Science, 
Hiroshima University Graduate School of Biomedical Sciences, Kasumi 1-2-3, 
Minami-ku, Hiroshima 734-8553, Japan 
2Department of Dental Pharmacology, Field of functional Physiology, Branch of 
Biophysiological Science, Okayama University Graduate School of Medicine and 
Dentistry, 2-5-1 Shikada, Okayama 700-8525, Japan 
3Department of Pharmacology, Division of Clinical Pharmaceutical Sciences, 
Hiroshima University Graduate School of Biomedical Sciences, Kasumi 1-2-3, 
Minami-ku, Hiroshima 734-8553, Japan 
 
The number of text page is 31.     The number of figures are 5. 
*Correspondence author. Tel.:+81-82-257-5640; fax: +81-82-257-5644. 
E-mail address: todohi@hiroshima-u.ac.jp 
 2
Abstract 
Platelet-activating factor (PAF) is a potent inflammatory lipid mediator in peripheral 
tissues. However, its role in mediation of nociception in central nervous system is 
unknown. In the present study, whether PAF plays some role in pain transduction in the 
spinal cord was studied in mice. Intrathecal injection of PAF induced tactile pain, tactile 
allodynia at as low as 10 fg ~ 1 pg with a peak response at 100 fg, while lyso-PAF was 
without effect in the range of doses. Tactile allodynia induced by PAF was blocked by a 
PAF receptor antagonists, TCV-309, WEB 2086 and BN 50739. The expression of PAF 
receptor mRNA by RT-PCR was observed in DRG and spinal cord in mice. ATP P2X 
receptor antagonists, pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid (PPADS) 
and 2’,3’-O-(2,4,6-trinitrophenyl) adenosine 5-triphosphate (TNP-ATP), NMDA 
receptor antagonist, MK 801 and nitric oxide synthetase inhibitor, 7-nitroindazole 
blocked the PAF-induced tactile allodynia. PAF-induced tactile allodynia and thermal 
hyperalgesia disappeared in neonatally capsaicin-treated adult mice, while tactile 
allodynia but not thermal hyperalgesia induced by intrathecally injected α,β-methylene 
ATP, a P2X receptor agonist, was capsaicin-insensitive. The present study demonstrated 
that PAF is a potent inducer of tactile allodynia and thermal hyperalgesia at the level of 
the spinal cord. PAF-evoked tactile allodynia is suggested to be mediated by ATP and 
the following NMDA and NO cascade through capsaicin-sensitive fiber, different from 
exogenously injected α,β-methylene ATP which is insensitive to capsaicin treatment. 
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1. Introduction 
 
Platelet-activating factor (PAF) is an alkyl-phospholipid, described in a variety of 
immune and inflammatory cells and an important mediator of the inflammatory 
responses. PAF has also been found in neuronal tissues. PAF is suggested to be 
implicated in a variety of physiological and pathological states in the central nervous 
system (CNS) (Ishii and Shimizu, 2000).  
Tissue damage or injury of neuron in periphery often cause hyperalgesia and tactile 
allodynia, the latter is a state in which innocuous tactile stimuli evoke pain. The 
mechanisms of the production of such pain hypersensitivity is not yet clear, but an 
increased responsiveness of neurons in the central nervous system is significantly 
relevant to the development of the pathological state. Prostaglandin is one of the critical 
mediators for the processing of pain at the spinal cord level and contribute to pain 
hypersensitivity, in addition to augmenting pain information at peripheral terminals of 
primary afferent nociceptors (Minami et al., 1999; Uda et al., 1990). Faden and Halt 
(1992) administered PAF intrathecally to examine its effects in the spinal cord and 
found that PAF decreased blood flow in the spinal cord, motor function or survival, 
suggesting the role of PAF in tissue damage after spinal cord injury. PAF antagonist 
treatment reduces pro-inflammatory cytokine mRNA after spinal cord injury, 
suggesting that PAF contributes to secondary damage after spinal cord injury 
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(Hostettler et al., 2002). Actually, PAF levels have been shown to be elevated by 
20-fold in spinal cord injured by ischemia and reperfusion (Lindsberg et al., 1990). 
Although these events suggest PAF as a signaling molecule triggering the inflammatory 
events in spinal cord, a potential role of PAF in the regulation of pain at spinal cord has 
not been considered. Recent studies stressed the importance of spinal glial cells for the 
regulation of pain hypersensitivity and tactile allodynia following peripheral nerve 
injury (Tsuda et al., 2003; 2004). The number of microglia increased in the dorsal horn 
on the side of nerve injury model (Aldskogius and Kozlva, 1998). PAF is released from 
stimulated microglia cells (Jaranowska et al., 1995) and is a potent chemotactic factor 
of microglia (Aihara et al., 2000). These evidence provide a possibility that PAF may 
serve as a regulator of pain at spinal cord. 
The present study investigated whether PAF plays some role in transducing pain at 
the spinal cord level by evaluating the development of tactile allodynia and thermal 
hyperalgesia after intrathecal administration of PAF. Recent studies suggest the central 
role of ATP/purinoceptors in spinal cord in mediating pain hypersensitivity (Tsuda et al., 
1999; 2000; 2003). It has been demonstrated that the NMDA receptor system plays an 
important role in the development of allodynia by drugs (Minami et al., 1994; 1995). 
We have recently demonstrated that ATP P2X ionotropic receptors following 
glutamate/NO systems in spinal cord are involved in the regulation of the development 
of allodynia. Therefore, the involvement of these systems in the effects of PAF was also 
studied. 
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2. Materials and methods 
 
2.1. Animals 
 
Male ICR mice weighing 18-22 g were used for general experiments and female 
mice at 5-6 weeks of pregnancy were obtained for experiments on neonatal mice. 
Animals were housed at 22 ± 2 °C and all procedures and handling of the animals were 
performed according to both the Guiding Principles for the Care and Use of Laboratory 
Animals approved by the Japanese Pharmacological Society and the guidelines of 
Hiroshima University, Hiroshima, Japan. 
 
2.2 Injections 
 
2.2.1. Intrathecal injection 
For intrathecal (i.t.) injection, the head of the mice was placed into plastic cap and 
the body was held with one hand as described previously (Fukuhara et al., 2000). A 
27-gauge needle attached to a Hamilton micro syringe was inserted into the 
subarachnoid space between the L5 and L6 vertebrate of conscious mice and 5 µl of 
drug solution was slowly injected as described by Hylden and Wilcox (1980).  
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2.2.2. Neonatal capsaicin treatment 
Neonatal ICR mice were injected subcutaneously with 50 mg/kg capsaicin or 
vehicle 2 and 5 days after birth, then 5- to 6- week-old mice were used for the present 
experiments. To verify desensitization after capsaicin treatment, chemo sensitivity was 
determined using the wiping test with 33 µM of capsaicin, 1 % ethanol containing 
saline (Jancsó et al., 1977) and only mice with a lack of chemosensitivity to capsaicin 
were used for experiments. 
 
2.3. General testing procedures 
 
2.3.1. Touch-evoked tactile allodynia  
After the i.t. injection of the drug solution or vehicle, each mouse was placed in an 
individual plastic cage. Tactile allodynia was assessed every 5 min by lightly stroking 
the flank of each mouse with a paintbrush. Tactile allodynia response was ranked as 
described by Minami et al. (1995): 0, no response; 1, mild squeaking with attempts to 
move away from the stroking probe; 2, vigorous squeaking, biting the stroking probe 
and strong efforts to escape from the stroking probe. Values were represented by the 
average of total score evaluated at each time point (possible maximum score at each 
time point: 2/mouse) during the time course study. In other studies, allodynia was 
assessed every 5 min over a 60 min period (12 trials) and the values were represented 
by the average of cumulative score (possible maximum score: 2/mouse at each time 
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point x 12 trials = 24/mouse). In some experiments, tactile allodynia was evaluated by 
measuring the paw withdrawal threshold in response to probing with a series of 
calibrated fine filaments. The animals were placed in a plastic cage. After allowing the 
animals to adapt to the environment for several min, numbered monofilaments (von 
Frey filaments; Stoelting, Wood Dale, IL, USA) were applied perpendicularly to the 
dorsum surface of the hind paws. The smallest filament that caused the animal to flinch 
or move the paw from the stimulus three times out of three trials was determined to be 
the mechanical threshold. The filament number was converted to buckling force (gm). 
 
2.3.2. Thermal hyperalgesia 
Warm-water tail-flick test and hot-plate test were carried out to assess the effects of 
agents on the thermal nociceptive threshold. For the warm-water tail-flick test, the tails 
of mice were immersed in warm water, 48 °C. The latency of tail flick was recorded. 
For the hot-plate test, mice were placed on a 52 ± 0.1 °C hot plate. The response 
latency to either a hind-paw lick or jump was recorded. In the absence of responses, 
animals were removed from the warm water or hot plate after 15 sec and 30 sec, 
respectively to avoid tissue injury, and 15 sec and 30 sec latencies were assigned as the 
respective responses. 
 
2.4. PCR analysis of PAF receptor 
To analyze expression of PAF receptor, total RNA and then cDNA were prepared 
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from mouse DRG neurons and dorsal horn using TRIzol RNA extraction and RT-PCR 
kits. 
The tissues were quickly lysed by the addition of TRIzol® reagent (Life 
Technologies, Rockville, MD). Total RNA was isolated according to the manufacturer’s 
instructions, with the addition of DNase I treatment (RNase-free DNase I; Roche 
Molecular Chemicals Indianapolis, IN) to eliminate residual genomic DNA. 
Oligo(dT)-primed first-strand cDNA synthesis was performed with 1st Strand cDNA 
Synthesis Kit for RT-PCR (AMV) (Boehringer Mannheim) using 10 µg of total RNA 
as a template in a total volume of 20 µl. Reaction conditions were as described by the 
manufacturer. For negative controls without reverse transcription, total RNA was 
diluted to give the same total RNA concentration as in the cDNA solutions. These 
control reactions using total RNA as a template were performed to exclude genomic 
DNA contamination. The reaction solution (20 µl) contained 0.5 µM primer (each for 
reverse and forward primers), 2 mM MgCl2, 0.2 mM dNTPs (each) and 0.5 units of Taq 
polymerase (Ampli Taq Gold, PerkinElmer, Roche Molecular System, Branchburry, 
NJ) in 1 x PCR buffer II supplied by the manufacturer. As a template, 2 µl of total RNA 
solution or 2 µl of cDNA solution was used. The primers used to amplify mouse PAF 
receptor were forward, 5’-cctagtgcccaataaggatggct-3’; reverse, 5’- 
taggagtctggttggctggc-3’ (size 530 bp). The cycling conditions were: 95 °C for 10 min, 
followed by 35 cycles, each consisting of denaturation at 94 °C for 30 sec, annealing at 
52 °C for 30 sec, and extension at 72 °C for 2 min, and a final extension at 72 °C for 10 
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min. PCR products were separated by migration on 1.6 % (W/V) agarose gels and 
visualized by staining with ethidium bromide. Products were excised and purified using 
QIAQuickTM gel extraction kit (Qiagen), then subjected to restriction digest analysis 
and automated sequencing. PCR products corresponding to the published mouse PAF 
receptor cDNA sequence were obtained. 
 
2.5. Experimental procedures 
 
The first experiment established whether PAF evokes tactile allodynia and thermal 
hyperalgesia and whether the responses are mediated by PAF receptors in the spinal 
cord. On the test day, a group of mice received a 5 µl intrathecal injection of either 
TCV-309, WEB 2086, BN 50739, PAF receptor antagonists, or vehicle for drugs. 
Tactile allodynia and thermal behavioral response threshold were assessed before and 
after the i.t. injection. Animals then received 5 µl of various concentrations of PAF or 
lyso-PAF, an inactive precursor of PAF. In some experiments, TCV-309 and PAF were 
simultaneously administered by i.t. injection of a mixed solution of TCV-309 and PAF. 
In an additional experiment, dorsal root ganglion and spinal cord were isolated from 
non-treated mice and mRNA was prepared for PCR reaction to identify the PAF 
receptor mRNA. 
A separate group of mice was used in the second experiment to determine the 
influence of P2X receptor antagonists, pyridoxalphosphate-6-azophenyl-2’,4’- 
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disulfonic acid (PPADS) and 2’,3’-O-(2,4,6-trinitrophenyl) adenosine 5-triphosphate 
(TNP-ATP), NMDA receptor antagonist, MK 801, and NO synthetase inhibitor, 
7-nitroindazole (7-NI) on PAF-induced tactile allodynia. On the test day, animals 
received spinal injection of 5 µl of either artificial cerebrospinal fluid (ACSF) or 9 
nmol of MK 801; or they received intraperitoneal injection of 25 mg/kg of 7-NI. One 
hundred ng of PAF were then injected intrathecally in a volume of 5 µl. Tactile 
allodynia response was assessed before and after administration of PAF. A combination 
of PPADS or TNP-ATP with 100 ng of PAF was administered as a 5 µl mixed solution 
of the two agents. Tactile allodynia response was assessed before and after the injection 
of PPADS or TNP-ATP alone and in combination with PAF. 
In the third experiment, neonatal mice were treated with capsaicin to evaluate the 
effect of capsaicin treatment on PAF- or α,β-methylene ATP -induced tactile allodynia 
and thermal response threshold. Either ACSF, 100 ng of PAF or 1 µg of α,β-methylene 
ATP was injected intrathecally in adult mice neonatally treated with the mixture of 
10 % ethanol and 10 % Tween-80 (vehicle for capsaicin) or capsaicin. Tactile allodynia 
and thermal behavioral response threshold were assessed 15 min after the injection. 
 
2.6. Drugs 
 
PAF, lyso-PAF, PPADS, α,β-methylene ATP, MK 801, 7-NI, capsaicin were 
obtained commercially. TCV-309, WEB 2086 and BN 50739 were donated from 
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Takeda Pharmaceutical Co., Boehringer Ingelheim KG, and Institute Henri Beaufour, 
respectively. PAF was dissolved in ethanol, the ethanol was removed from an aliquot in 
a siliconized tube by introducing nitrogen gas into the tube and then dissolved in ACSF. 
Capsaicin was dissolved in the mixture of 10 % ethanol and 10 % Tween-80 in sterile 
saline, while 7-NI was dissolved in the mixture of 10 % dimethyl sulfoxide (DMSO) 
and 30 % propylene glycol in distilled water. BN 50739 dissolved in DMSO and 
diluted appropriately (final concentration of DMSO was 0.1 %). Other reagents were 
dissolved in ACSF. ACSF composition (in mM) was NaCl 142, KCl 5, CaCl2 2, MgCl2 
2, NaH2PO4 1.25, D-glucose 10, HEPES 10, 0.05% fatty acid-free bovine serum 
albumin, pH 7.4. 
 
2.7. Statistical analysis 
 
The results are presented as mean ± S.E.M. Thermal hyperalgesia data were 
analyzed by parametric ANOVA and significance (p<0.05) was further examined by 
Duncan’s test. Data for tactile allodynia were analyzed by non-parametric ANOVA and 
significance (p<0.05) was further examined by Fisher’s protected least significant 
difference (Fisher’s PLSD) test for multiple-comparison. Student’s t test was also used. 
p<0.05 was considered significant. 
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3. Results 
 
3.1. Effect of i.t. PAF on mechanical tactile allodynia and thermal hyperalgesia 
 
The i.t. administration of PAF at 100 fg per mouse induced prominent agitation 
responses, such as biting, vocalization and escape from the probe, when tactile stimuli 
with a paintbrush was applied to the flank of each mouse. Strong responses were 
evoked shortly after the injection when the maximal score was obtained, persisted for 
60 min, then gradually recovered over a 10 hr period (Fig. 1A). Tactile allodynia was 
evaluated by measuring the paw withdrawal threshold in response to probing with a 
series of calibrated fine filaments (von Frey hairs) (Fig. 1B). The threshold was 
markedly reduced after the administration of PAF and the time-course was similar to 
that of agitation responses. The administration of artificial cerebrospinal fluid did not 
induce any allodynic responses. These results indicate that the intrathecally injected 
PAF evokes strong pain by innocuous tactile stimuli. 
In the warm-water tail-flick test and hot-plate test, non-treated mice and 
ACF-treated control mice responded with constant latencies. PAF at a dose of 100 fg 
shortened these response times (response time in non-treated mice, ACSF-treated mice 
and PAF 100 fg-treated mice were 1.4 ± 0.1, 1.5 ± 0.2 and 0.6 ± 0.1 sec in warm-water 
tail-flick test, and those are 9.8 ± 0.6, 9.6 ± 0.8 and 4.7 ± 0.4 sec in hot-plate test, 
respectively. Significantly different from control, P<0.01, n=10). These findings 
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demonstrated that mice injected with PAF had developed thermal hyperalgesia. 
Intrathecal administration of PAF as low as 10 to 100 fg dose-dependently produced 
tactile allodynia in mice with peak response at 100 fg to 1 pg. Lyso-PAF was without 
effect in this range of dosages (Fig. 2A). Mice treated with more than 1 µg of PAF died, 
although lyso-PAF did not cause death at doses up to 10 µg. Tactile allodynic response 
induced by 100 fg PAF was antagonized by the simultaneous administration of a PAF 
receptor antagonist, TCV-309, 15 fmol, and blocked completely by the pretreatment of 
TCV-309, WEB 2086 and BN 50739 (Fig. 2B). Thermal hyperalgesic response to PAF 
was also blocked by PAF receptor antagonists (data not shown). Thus, the tactile 
allodynia and thermal hyperalgesia induced by PAF are mediated by PAF receptor 
stimulation.  
 
3.2. Expression of PAF receptor 
 
To evaluate the expression of PAF receptor mRNA in DRG and spinal cord, 
RT-PCR was performed using specific primers for mouse PAF receptor designed using 
the known sequence of PAF receptor. RT-PCR demonstrated specific amplification of 
530 bases expected size of PAR-receptor transcript in DRG and spinal cord to a lesser 
extent (Fig. 3). As a positive control, the lung where the density of the PAF receptor 
expression is known to be very high showed high amplification. There was no 
amplification in spleen where PAF receptor is known to be unexpressed (data not 
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shown). There was no amplification without RT reaction in each tissue. The similar 
results were obtained from 3 independent total RNA derived from each tissue.  
 
3.3. Effects of blockers for P2X receptor, NMDA receptor and NOS 
 
ATP P2X receptors, NMDA receptors and NO have been suggested to be involved 
in the development of tactile allodynia. To test whether PAF-induced tactile allodynia  
is mediated through these signaling cascatde, the effects of various inhibitors of this 
cascade on PAF-induced tactile allodynia were evaluated. PPADS, an antagonist of 
P2XR subtypes P2X1,2,3,5,7R reduced by about 70 % of PAF-induced tactile allodynia at 
0.3 nmol and showed no further reduction even at a higher dose of 5 nmol, while 
TNP-ATP, an antagosint of P2XR subtypes P2X1-4R completely inhibited the tactile 
allodynia (Fig.4). NMDA receptor antagonist, MK 801 and an NO synthetase inhibitor, 
7-NI, all inhibited the production of tactile allodynia induced by PAF. Therefore, 
PAF-induced tactile allodynia may be mediated by purine and NMDA receptor, and NO 
systems. 
 
3.4. Effects of capsaicin treatment on PAF-induced thermal hyperalgesia and tactile 
allodynia  
 
Whether the intrathecal injection of PAF produces thermal hyperalgesia was 
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examined in warm-water tail-flick test (Fig. 5A) and hot-plate test in normal mice and 
capsaicin-treated mice. Non-treated mice and ACSF-treated control mice responded to 
the thermal stimuli with constant latencies of 1.4 ± 0.1 and 1.5 ± 0.2 sec in warm-water 
test. PAF shortened tail-flick response time (0.6 ± 0.1 sec) at a dose of 100 fg (Fig. 5A). 
The i.t. administration of 1 µg of α,β-methylene ATP, tested as a reference compound, 
reduced the latency period of tail-flick response time (1.1 ± 0.2 sec). 
Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a neurotoxin that causes the 
destruction of mainly unmyelinated, small-diameter fibers when administered to 
neonatal animals. In mice that had been neonatally treated with capsaicin, the response 
times to thermal stimuli in ACSF-injected control mice (1.5 ± 0.2 sec) were prolonged 
to 2.7 ± 0.3 sec on tail-flick test (Fig. 5A). Neither PAF nor α,β-methylene ATP 
affected the response time on tail-flick test in capsaicin-treated mice (Fig. 5A). There 
were no effects of PAF and α,β-methylene ATP on hot-plate test either in 
capsaicin-treated mice (data not shown). These results demonstrated that mice had 
developed thermal hyperalgesia mediated by capsaicin-sensitive fiber. To test whether 
PAF-induced tactile allodynia is mediated by capsaicin-sensitive fiber, mice 
intrathecally injected with PAF were challenged with innocuous stimuli. In normal mice 
intrathecally injected with PAF 100 fg, an innocuous tactile stimuli applied to the flank 
of the mouse with a paint-brush evoked an allodynic response. In capsaicin-treated 
mice, PAF failed to evoke tactile allodynia, while α,β-methylene ATP still evoked 
tactile allodynia (Fig. 5B). In the paw withdrawal response to probing with a series of 
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von Frey hairs, the threshold was markedly reduced in PAF-treated mice in comparison 
to that in ACSF-treated control mice. PAF failed to reduce the threshold in 
capsaicin-treated mice (Fig. 5C). 
These results show that PAF-induced tactile allodynia was capsaicin-sensitive as 
well as PAF-induced thermal hyperalgesia, while α,β-methylene ATP-induced tactile 
allodynia is capsaicin-insensitive. 
 
4. Discussion 
Although PAF injected into the rat hindpaw causes thermal hyperalgesia, there is 
dissociation between the induction of edema and that of hyperalgesia with regard to the 
doses of PAF required (PAF induced edema from 5 ng, and hyperalgesia from 1.25 µg), 
time course of the phenomena (hyperalgesia is a delayed response than edema) and in 
the drugs able to antagonize their development (Bonnet et al., 1981; Dallob et al., 1987; 
Vargaftig and Ferreira, 1981). In healthy volunteers, PAF injected intradermally 
induced weheal and flare responses and subsequently erythema and cellular infiltration. 
The effects of PAF were much potent than those of PGE2, but there was no hyperalgesia 
demonstrated by PAF, although intradermal PGE2 induced hyperalgesia (Sciberras et al., 
1987). Thus, the role of PAF in pain production does not seem striking compared to its 
pro-inflammatory action in the periphery. The present study demonstrated that 
intrathecal injection of PAF evoked potent and long-lasting tactile pain and thermal 
hyperalgesia in mice. The effects of PAF seem to be mediated by PAF receptor, because 
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TCV-309, a selective PAF receptor antagonist (Terashita et al., 1992) as well as WEB 
2086 and BN 50739 blocked the behavioral response to PAF. Lyso-PAF, an inactive 
intermediate for PAF receptor, was without effect at this range of dosage. The 
distribution of PAF receptor has been demonstrated in a variety of cells and tissues 
including the CNS (Ishii and Shimizu, 2000). Actually RT-PCR demonstrated the 
specific amplification in mouse DRG neuron and spinal cord in the present study.  
PAF is suggested to serve as a transmitter in the central nervous system based on 
the formation of PAF upon stimulation of nervous tissue, the presence of PAF receptor 
and the ability of PAF to activate the functions of neuronal cells (Bito et al., 1992; 
Catalan et al., 1992; Honda et al., 1991; Sogos et al., 1990). We have previously 
observed that PAF by itself did not evoke any secretory response in adrenal chromaffin 
cell where the expression of PAF receptor was demonstrated, but markedly potentiated 
ACh-induced catecholamine release (Morita et al., 1995), suggesting the modulating 
role of PAF on secretory response. As PAF receptor mRNA is detected in DRG, if PAF 
receptor expressed in nerve terminal of primary afferent neuron in spinal cord, the 
stimulation of the PAF receptors could contribute to facilitate the release of 
neurotransmitters for pain evoked by peripheral nociceptive stimulation as discussed 
below.  
ATP has been proposed as a transmitter candidate for primary afferent neurons and 
may be involved in spinal nociceptive transmission (Driessen et al., 1994; Li et al., 
1998) as well as in peripheral nerve ending (for review, see Burnstock and Wood, 1996; 
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Ralevic and Burnstock, 1998). Recent study demonstrated that tactile allodynia could 
be induced by plantar or intrathecal application of α,β-methylene ATP, an agonist of 
P2X receptor subtypes P2X1,3R and PPADS, an antagonist of P2XR subtypes 
P2X1,2,3,5,7R blocked tactile allodynia induced by α,β-methylene ATP (Fukuhara et al., 
2000; Tsuda et al., 2000), suggesting that P2X1,3 receptors in the spinal cord is involved 
in the development of tactile allodynia. PPADS, reduced but did not block completely 
PAF-induced tactile allodynia even at high dosage, while TNP-ATP, an antagosint of 
P2XR subtypes P2X1-4R completely inhibited the tactile allodynia. Thus, it may be 
suggested that PAF-induced tactile allodynia is mediated by stimulation of several P2X 
receptor subtypes such as P2X1,3,4 receptors in the spinal cord. It has been reported that 
ATP is co-released with other neurotransmitter such as GABA in the spinal cords (Jo 
and Schlichter, 1999). Whether PAF stimulates ATP release remains to be elucidated.  
Although the mechanisms for drug-induced tactile allodynia remain unclear, 
activation of the glutamate/NO system is thought to play an important role in 
drug-induced tactile allodynia. This idea is based on the following evidence; 1) 
drugs-induced tactile allodynia is blocked by NMDA receptor antagonists (Fukuhara et 
al., 2000; Ishikawa et al., 2000; Minami et al., 1994; 1995; 2001; Onaka et al., 1996; 
Turnbach and Randich, 2002), NO synthetase inhibitor (Fukuhara et al., 2000; Minami 
et al., 1994; 1995) or eliminated in mice genetically disrupted with GluR subtype 
(Minami et al., 2001), 2) intrathecal administration of glutamate and NO donors 
induced tactile allodynia in conscious mice (Minami et al., 1994), 3) PGE2 stimulated 
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glutamate release (Malmberg et al., 1995; Nishihara et al., 1995) and NO release (Sakai 
et al., 1998) in the spinal cord. PAF-induced tactile allodynia was also inhibited by the 
intrathecal injection of MK 801, a noncompetitive antagonist of NMDA receptor, and 
of 7-NI, an inhibitor of NO synthetase. Consistent with these previous findings, the 
present results suggested that the activation of spinal PAF receptors elicits tactile 
allodynia via the pathway of P2X receptors, NMDA receptors and NO.  
Systemic administration of capsaicin to neonatal mice is known to selectively 
destroy capsaicin-sensitive neurons (Jancsó et al., 1977). Tsuda et al. (2000) reported 
that thermal hyperalgesia induced by α,β-methylene ATP injection into the rat hindpaw 
were lost in neonatally capsaicin-treated adult rats, while mechanical tactile allodynia 
remained, suggesting that the mechanical tactile allodynia is signaled by distinct 
primary afferent neurons from that for thermal hyperalgesia. We have also observed 
that thermal hyperalgesia induced by intrathecally administered α,β-methylene ATP 
was sensitive to capsaicin-treatment while tactile allodynia was insensitive. However, 
tactile allodynia as well as thermal hyperalgesia induced by intrathecal PAF were 
disappeared in capsaicin-treated mice, nevertheless PAF-induced tactile allodynia  is 
suggested to be mediated by spinal ATP/P2X receptor activation. One exponent for the 
difference between PAF- and α,β-methylene ATP-induced tactile allodynia in capsaicin 
sensitivity could be possible as follow. Several ATP receptor subtypes were expressed 
both presynaptically in the terminals of primary afferent fibers where the activation of 
presynaptic P2X receptors elicits glutamate release (Gu and MacDermott, 1997) and 
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postsynaptically in dorsal horn (Brake et al., 1994; Chen et al., 1995; Cook et al., 1997). 
Therefore, exogenously administered α,β-methylene ATP into the spinal cord can act 
on both pre-synaptic P2X receptors located in either capsaicin-sensitive or insensitive 
neurons and post-synaptic P2X receptors. This may explain the insensitivity of 
α,β-methylene ATP-induced tactile allodynia to capsaicin. The present evidence that 
PAF-induced tactile allodynia was lost in capsaicin-treated mice would suggest that 
ATP is selectively released by PAF from capsaicin-sensitive neurons or endogenously 
derived ATP by PAF acts on capsaicin-sensitive neurons. The evidence that neonatal 
capsaicin treatment eliminated NMDA-induced tactile allodynia (Minami et al., 2001) 
further support NMDA-mediation of PAF-induced allodynia via capsaicin-sensitive 
neuron.  
For the source of PAF in spinal cord, glial cells or immune and inflammation 
related cells could be responsible in pathological states. PAF levels have been shown to 
be elevated in spinal cord injured (Lindsberg et al., 1990) and contributes to the robust 
inflammatory responses in acute phase and spread of secondary injury (Faden and Halt, 
1992; Hostettler and Carlson, 2002). The significant relevance of microglia to pain 
hypersensitivity has been demonstrated; the number of microglia accumulated in the 
dorsal horn on the side of nerve injury model (Aldskogius and Kozlva, 1998), and an 
activation of P2X4 receptors in spinal hyperactive microglia mediates tactile allodynia 
after nerve injury via the activation of p38MAPK signaling pathway (Tsuda et al., 
2003; 2004). Stimulated microglia cells produces PAF (Jaranowska et al., 1995). PAF 
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receptor mRNA and functional expression are the most abundant in microglia (Mori et 
al., 1996) and PAF functions as a potent chemotactic factor of microglia (Aihara et al., 
2000). In addition, PAF receptors function to stimulate the production of NO (Cardile et 
al., 1996), PGE2 (Teather and Wurtman, 2003) or NGF (Brodie, 1995) in astrocytes. 
The expression of mRNA of PAF receptor by RT-PCR in spinal cord in the present 
study may reflect the gene of glial cells. Thus, there is a possibility that the interaction 
between glia and neuron mediated by PAF contributes to form network for pain signals 
for hypersensitivity in pathological states. Taken together, PAF may be produced in a 
variety of cells in spinal cord under pathological conditions and be a candidate for 
mediator of noxious stimuli. 
 
Acknowledgements 
 
This work was supported in part by a Grant-in-Aid for Scientific Research from the 
Ministry of Education, Science, Sports and Culture of Japan. The authors wish to thank 
Dr. Z. Terashita (Takeda Pharmaceutical Co. Kyoto, Japan), Dr. P. Braquet (Institute 
Henri Beaufour, Le Plessis Robinson, France) and Prof. H.M. Jennewein (Boehringer 
Ingelheim KG, Ingelheim am Rhein, Germany) for generously donating TCV-309, 
BN50739 and WEB 2086, respectively. 
 
 
 22
References 
 
Aihara M, Ishii S, Kume K, Shimizu T. Interaction between neurone and microglia 
mediated by platelet-activating factor. Genes Cells 2000; 5:397-406. 
Aldskogius H, Kozlova EN. Central neuron-glial and glial-glial interactions following 
axon injury. Prog Neurobiol 1998;55:1-26. 
Bito H, Nakamura M, Honda Z, Izumi T, Iwatsubo T, Seyama Y, Ogura A, Kudo Y, 
Shimizu T. Platelet-activating factor (PAF) receptor in rat brain: PAF mobilizes 
intracellular Ca2+ in hippocampal neurons. Neuron 1992;9:285-294. 
Bonnet J, Loiseau AM, Orvoen M, Bessin P. Platelet-activating factor acether 
(PAF-acether) involvement in acute inflammatory and pain processes. Agents 
Actions 1981;11:559-562. 
Brake AJ, Wagenbach MJ, Julius D. New structural motif for ligand-gated ion channels 
defined by an ionotropic ATP receptor. Nature 1994;371:519-523. 
Brodie C. Platelet activating factor induces nerve growth factor production by rat 
astrocytes. Neurosci Lett 1995;186:5-8. 
Burnstock G, Wood JN. Purinergic receptors: their role in nociception and primary 
afferent neurotransmission. Curr Opin Neurobiol 1996;6:526-532. 
Cardile V, Jiang X, Renis M, Bindoni M. Effects of ether lipid 
1-O-octadecyl-2-methoxy-rac-glycero-3-phosphocholine and its analogs PAF and 
 23
CPAF on the release of nitric oxide in primary cultures of rat astrocytes. Brain 
Res 1996;715:98-103. 
Catalan RE, Martinez AM, Aragones MD, Fernandez I, Lombardia M, Miguel BG. 
PAF-induced activation of polyphosphoinositide-hydrolyzing phospholipase C in 
cerebral cortex. Biochem Biophys Res Commun 1992;183:300-305. 
Chen CC, Akopian AN, Sivilotti L, Colquhoun D, Burnstock G, Wood JN. A P2X 
purinoceptor expressed by a subset of sensory neurons. Nature 1995;377: 
428-431. 
Cook SP, Vulchanova L, Hargreaves KM, Elde R, McCleskey EW. Distinct ATP 
receptors on pain-sensing and stretch-sensing neurons. Nature 1997;387:505-508. 
Dallob A, Guindon Y, Goldenberg MM. Pharmacological evidence for a role of 
lipoxygenase products in platelet-activating factor (PAF)-induced thermal 
hyperalgesia. Biochem Pharmacol 1987;36:3201-3204. 
Driessen B, Reimann W, Selve N, Friderichs E, Bultmann R. Antinociceptive effect of 
intrathecally administered P2-purinoceptor antagonists in rats. Brain Res 
1994;666:182-188. 
Faden AI, Halt P. Platelet-activating factor reduces spinal cord blood flow and causes 
behavioral deficits after intrathecal administration in rats through a specifc 
receptor mechanism. J Pharmcol Exp Ther 1992;261:1064-1070. 
 24
Fukuhara N, Imai Y, Sakakibara A, Morita K, Kitayama S, Tanne K, Dohi T. 
Regulation of the development of allodynia by intrathecally administered P2 
purinoceptor agonists and antagonists in mice. Neurosci Lett 2000;292:25-28. 
Gu JG, MacDermott AB. Activation of ATP P2X receptors elicits glutamate release 
from sensory neuron synapses. Nature 1997;389:749-753. 
Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okado H, Ito K, 
Miyamoto T, Shimizu T. Cloning by functional expression of platelet-activating 
factor receptor from guinea-pig lung. Nature 1991;349:342-346. 
Hostettler ME, Carlson SL. PAF antagonist treatment reduces pro-inflammatory 
cytokine mRNA after spinal cord injury. NeuroReport 2002;13:21-24. 
Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J 
Pharmacol 1980;67:313-316. 
Ishii S, Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered 
PAF receptor mutant mice. Prog Lipid Res 2000;39:41-82. 
Ishikawa T, Marsala M, Sakabe T, Yaksh TL. Characterization of spinal amino acid 
release and touch-evoked allodynia produced by spinal glycine or GABAA 
receptor antagonist. Neuroscience 2000;95:781-786. 
Jancsó G, Kiraly E, Jancso-Gabor A. Pharmacologically induced selective degeneration 
of chemosensitive primary sensory neurones. Nature 1977;270:741-743. 
Jaranowska A, Bussolino F, Sogos V, Arese M, Lauro GM, Gremo F. 
Platelet-activating factor production by human fetal microglia. Effect of 
 25
lipopolysaccharides and tumor necrosis factor-alpha. Mol Chem Neuropathol 
1995;24:95-106. 
Jo Y-H, Schlichter R. Synaptic corelease of ATP and GABA in cultured spinal neurons. 
Nat Neurosci 1999;2:241-245. 
Li P, Calejesan AA, Zhuo M. ATP P2X receptors and sensory synaptic transmission 
between primary afferent fibers and spinal dorsal horn neurons in rats. J 
Neurophysiol 1998;80:3356-3360. 
Lindsberg PJ, Yue TL, Frerichs KU, Hallenbeck JM, Feuerstein G. Evidence for 
platelet-activating factor as a novel mediator in experimental stroke in rabbits. 
Stroke 1990;21:1452-1457. 
Malmberg AB, Hamberger A, Hedner T. Effects of Prostaglandin E2 and capsaicin on 
behavior and cerebrospinal fluid amino acid concentrations of unanesthetized rats: 
a microdialysis study. J Neurochem 1995;65:2185-2193. 
Minami T, Matsumura S, Okuda-Ashitaka E, Shimamoto K, Sakimura K, Mishina M, 
Mori H, Ito S. Characterization of the glutamatergic system for induction and 
maintenance of allodynia. Brain Res 2001;895:178-185. 
Minami T, Nishihara I, Ito S, Sakamoto K, Hyodo M, Hayaishi O. Nitric oxide 
mediates allodynia induced by intrathecal administration of prostaglandin E2 or 
prostaglandin F2α in conscious mice. Pain 1995;61:285-290. 
Minami T, Nishihara I, Uda R, Ito S, Hyodo M, Hayaishi O. Involvement of glutamate 
receptors in allodynia induced by prostaglandins E2 and F2α injected into 
 26
conscious mice. Pain 1994;57:225-231. 
Minami T, Okuda-Ashitaka E, Hori Y, Sakuma S, Sugimoto T, Sakimura K, Mishina M, 
Ito S. Involvement of primary afferent C-fibers in touch-evoked pain (allodynia) 
induced by prostaglandin E2. Eur J Neurosci 1999;11:1849-1856. 
Mori M, Aihara M, Kume K, Hamanoue M, Kohsaka S, Shimizu T. Predominant 
expression of platelet-activating factor receptor in the rat brain microglia. J 
Neurosci 1996;16:3590-3600. 
Morita K, Suemitsu T, Uchiyama Y, Miyasako T, Dohi T. Platelet-activating factor 
mediated potentiation of stimulation-evoked catecholamine release and the rise in 
intracellular free Ca2+ concentration in adrenal chromaffin cells. J Lipid Mediat 
Cell Signal 1995;11:219-230. 
Nishihara I, Minami T, Watanabe Y, Ito S, Hayaishi O. Prostaglandin E2 stimulates 
glutamate release from synaptosomes of rat spinal cord. Neurosci Lett 
1995;196:57-60. 
Onaka M, Minami T, Nishihara I, Ito S. Involvement of glutamate receptors in 
strychnine- and bicuculline-induced allodynia in conscious mice. Aneshesiology 
1996;84:1215-1222. 
Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 
1998;50:413-492. 
Sakai M, Minami T, Hara N, Nishihara I, Kitada H, Kamiyama Y, Okuda K, Takahashi 
H, Mori H, Ito S. Stimulation of nitric oxide release from rat spinal cord by 
 27
prostaglandin E2. Br J Pharmacol 1998;123:890-894. 
Sciberras DG, Goldenberg MM, Bolognese JA, James I, Baber NS. Inflammatory 
responses to intradermal injection of platelet activating factor, histamine and 
prostaglandin E2 in healthy volunteers: a double blind investigation. Br J Clin 
Pharmacol 1987;24:753-761. 
Sogos V, Bussolino F, Pilia E, Torelli S, Gremo F. Acetylcholine-induced production of 
platelet-activating factor by human fetal brain cells in culture. J Neurosci Res 
1990;27:706-711. 
Teather LA, Wurtman RJ. Cyclooxygenase-2 mediates platelet-activating 
factor-induced prostaglandin E2 release form rat primary astrocytes. Neurosci Lett 
2003;340:177-180. 
Terashita Z, Takatani M, Nishikawa K. Pharmacological profile of TCV-309--a potent 
PAF antagonist. J Lipid Mediat 1992;5:183-185. 
Tsuda M, Koizumi S, Kita A, Shigemoto Y, Ueno S, Inoue K. Mechanical allodynia 
caused by intraplantar injection of P2X receptor agonist in rats: involvement of 
heteromeric P2X2/3 receptor signaling in capsaicin-insensitive primary afferent 
neurons. J Neurosci 2000;20:RC90:1-5. 
Tsuda M, Mizokoshi A, Shigemoto-Mogami Y, Koizumi S, Inoue K. Activation of p38 
mitogen-activated protein kinase in spinal hyperactive microglia contributes to 
pain hypersensitivity following peripheral nerve injury. Glia 2004;45:89-95. 
Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, 
 28
Inoue K. P2X4 receptors induced in spinal microglia gate tactile allodynia after 
nerve injury. Nature 2003;424:778-783. 
Tsuda M, Ueno S, Inoue K. In vivo pathway of thermal hyperalgesia by intrathecal 
administration of α,β-methylene ATP in mouse spinal cord: Involvement of the 
glutamate-NMDA receptor system. Br J Pharmacol 1999;127:449-456. 
Turnbach ME, Randich A. The role of spinal neurokinin-1 and glutamate receptors in 
hyperalgesia and allodynia induced by prostaglandin E2 or zymosan in the rat. 
Pain 2002;97:127-137. 
Uda R, Horiguchi S, Ito S, Hyodo M, Hayaishi O. Nociceptive effects induced by 
intrathecally administration of prostaglandin D2, E2, or F2α to conscious mice. 
Brain Res 1990; 510:26-32. 
Vargaftig BB, Ferreira SH. Blockade of the inflammatory effects of platelet-activating 
factor by cyclo-oxygenase inhibitors. Braz J Med Biol Res 1981;14:187-189. 
 
 
 
 
 29
Figure legends 
 
Fig. 1. The time course of tactile allodynia induced by intrathecally injected PAF in 
mice. 
A: Tactile allodynia was assessed by light stroking of the flank of each mouse with a 
paintbrush. Each point represents the average of score evaluated at each time point. B: 
Tactile allodynia was assessed by measuring the paw withdrawal threshold in response 
to probing with von Frey hairs. Control mice were injected with vehicle; artificial 
cerebrospinal fluid (ACSF). N=12-19 mice per group. 
 
Fig.2.  The dose-response relationship of PAF- and lyso-PAF-induced tactile allodynia 
in mice (A). Tactile allodynia was assessed by light stroking of the flank of each mouse 
with a paintbrush. Each point represents the average of cumulative score evaluated 
every 5 min for 60 min. B: Blockade of PAF-induced tactile allodynia by PAF receptor 
antagonists. Antagonists were injected intrathecally in a solution containing PAF 
(simultaneously) or 60 min before the injection of PAF. N=9-20 mice per group. 
**p<0.01 compared with the vehicle (i.t.)-injected group (Fisher’s PLSD test). 
 
Fig.3. RT-PCR analysis of the expression of mouse PAF receptor mRNA 
cDNA fragments of mouse PAF receptor (530 bp) were amplified from DRG (lane 1 
and 5), dorsal horn (SP; lane 2 and 6), and lung (lane 3 and 7) cDNA, as described in 
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Materials and Methods. Lanes 5, 6, and 7; negative controls, in which RT was omitted. 
Lane 4; positive control, cDNA of mouse PAF receptor. 
 
Fig.4. Effects of P2X receptor antagonists (PPADS and TNP-ATP), NMDA receptor 
antagonist (MK 801) and NO synthase inhibitor (7-NI) on PAF-induced tactile 
allodynia in mice. Tactile allodynia was assessed by light stroking of the flank of each 
mouse with a paintbrush after the intrathecal injection of PAF, 0.1 pg. Each point 
represents the average of cumulative score evaluated every 5 min for 60 min. 
Intrathecal injection of PPADS and TNP-ATP were performed simultaneously with PAF. 
MK 801 was injected intrathecally 60 min before the injection of PAF. 7-nitroindazole 
(7-NI) was injected intraperitoneally 15 min before the injection of PAF. N=10-20 mice 
per group. **p<0.01 compared with the vehicle-injected group (Fisher’s PLSD test). 
 
Fig. 5. Effects of PAF and α,β-methylene ATP on thermal hyperalgesia and tactile 
allodynia in control and neonatally capsaicin-treated adult mice. A: Thermal 
hyperalgesia was evaluated by warm-water tail-flick test 15 min after the intrathecal 
injection of ACSF, PAF and α,β-methylene ATP (α,β-me-ATP). B: Tactile allodynia 
was assessed by light stroking of the flank of the mice with paintbrush after the 
intrathecal injection of ACSF, PAF and α,β-me-ATP. Each point represents the average 
of cumulative score evaluated every 5 min for 60 min. C: Tactile allodynia was 
assessed by measuring paw withdrawal threshold in response to probing with von Frey 
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hairs at 15 min after the intrathecal injection of ACSF, PAF and α,β-me-ATP. N=8-30 
mice per group. #p<0.05, ##p<0.01 compared with the respective ACSF (i.t.)-injected 
group (Duncan’s test). **p<0.01 compared with the respective ACSF (i.t.)-injected 
group (Fisher’s PLSD test). ††p<0.01 compared with the respective vehicle (s.c.) 
treated group (Student’s t test). 
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